GlassScriptPhysician profile
Sarah Powell
NPI 1306249438
$3,026.12
in general payments reported to CMS, 2019-2025
25 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $753 · 2022: $729 · 2023: $530 · 2024: $436 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.81 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $297.14 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $296.38 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $243.19 | 2022-2025 | Fanapt, Hetlioz |
| Corium, LLC | $224.41 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $204.50 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $199.63 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.30 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $152.07 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $119.43 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $80.00 | 2022-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $68.56 | 2022 | |
| Neurocrine Biosciences, INC. | $56.09 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $55.92 | 2021-2023 | Jornay Pm |
| Neos Therapeutics, LP | $55.42 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $52.89 | 2021-2022 | |
| Microtransponder, INC. | $48.15 | 2025 | |
| Supernus Pharmaceuticals, INC. | $46.43 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $33.85 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $25.22 | 2025 | Cobenfy |
| Bausch Health US, LLC | $24.35 | 2021 | |
| Noven Therapeutics, LLC | $20.43 | 2024 | Secuado, Xelstrym |
| Axsome Therapeutics, INC. | $20.19 | 2023 | Auvelity |
| Tris Pharma INC | $18.78 | 2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.98 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.